


FUNCTIONAL ROLE OF OVEREXPRESSED GENES IN *iAMP21*+ B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

JÚLIO CÉSAR SANTORO¹; LUIZA ABDO²; MARCO PRETTI²; MARTIN BONAMINO²; MICHELE PEREIRA³; FERNANDA COSTAS CASAL³; ANA CLARA BASTOS⁴; MARIANA CONCENTINO⁴; ETEL GIMBA^{4,5}; MARIANA EMERENCIANO¹


¹Molecular Cancer Study group, Division of Clinical Research, Research Center, INCA-RJ, Brazil. ²Molecular Carcinogenesis Program, Research Center, INCA-RJ, Brazil. ³Laboratory of Hemato-Cellular and Molecular Oncology, Hemato-Molecular Oncology Research Program, Research Center, INCA-RJ, Brazil. ⁴Group of Structural and Molecular Oncobiology, Cell Biology Program, Research Center, INCA-RJ, Brazil. ⁵Department of Nature Sciences, IHS, UFF-RJ, Brazil.

INTRODUCTION


AMP21 has been described in 2% of B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and is associated with unfavorable prognosis due to high relapse risk (Fig. 1).



A striking feature is that all patients exhibit a common region of amplification at chromosome 21 (*ERG* and *ETS2* genes), as well as overexpression of *LGMN* gene (Fig. 2).



Additionally, it has been recently shown that *OPN* is differentially expressed in BCP cells at the time of relapse (Fig. 3).



It has been described that *ERG*, *ETS2* and *LGMN* play key roles in cell differentiation. Besides, deregulated expression of these genes in other tumor types has been associated with poor prognosis and/or resistance to chemotherapy.

HYPOTHESIS


Deregulated expression of *ERG*, *ETS2*, *LGMN* and *OPN* is correlated with chemotherapeutic resistance (CR) in BCP-ALL.

OBJECTIVE


To evaluate the role of *ERG*, *ETS2*, *LGMN* and *OPN* in ALL CR.

METHODS

Experimental design



RESULTS



However, *ERG*, *ETS2* and *LGMN* transcripts were downregulated when *OPNc* was knocked-down in BCP-ALL cell lines.

CONCLUSION

Our preliminary data suggest that expression of evaluated genes can be differentially modulated upon *LGMN* or *OPNc* silencing in each leukaemia cell lineage subtype.

PERSPECTIVES

Functional *in vitro* assays are ongoing to evaluate their roles in CR.

Financial support:

Projeto Gráfico: Área de Edição e Produção de Materiais Técnico-Científicos / INCA